Key Points
- Director James Aloysius Brady sold 10,834 shares of Xeris on March 30 at an average price of $5.54 (totaling $60,020.36), reducing his stake by 10.83% to 89,166 shares; the transaction was disclosed in an SEC filing.
- Xeris reported $0.06 EPS for the quarter versus $0.03 expected and revenue of $85.81M (vs. $86.00M consensus), with a net margin of 0.19% and a negative return on equity of 5.33%.
- The stock has a market cap of $1.04B and a one‑year range of $3.81–$10.08, while analysts hold a consensus rating of "Moderate Buy" with a consensus target price of $10.80.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director James Aloysius Brady sold 10,834 shares of the business's stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $5.54, for a total value of $60,020.36. Following the sale, the director owned 89,166 shares in the company, valued at approximately $493,979.64. This represents a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Xeris Biopharma Stock Performance
Shares of NASDAQ XERS opened at $6.04 on Friday. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -603.40 and a beta of 0.77. Xeris Biopharma Holdings, Inc. has a one year low of $3.81 and a one year high of $10.08. The business has a fifty day simple moving average of $6.36 and a 200 day simple moving average of $7.30. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The firm had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. Sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.
Wall Street Analyst Weigh In
XERS has been the topic of a number of analyst reports. Barclays initiated coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They issued an "overweight" rating and a $9.00 target price on the stock. Wall Street Zen raised Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a report on Saturday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Weiss Ratings raised Xeris Biopharma from a "sell (d-)" rating to a "hold (c-)" rating in a report on Wednesday, March 4th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.
Read Our Latest Analysis on Xeris Biopharma
Institutional Trading of Xeris Biopharma
Several hedge funds have recently modified their holdings of XERS. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the 4th quarter worth approximately $25,000. AlphaQuest LLC bought a new position in Xeris Biopharma in the 3rd quarter valued at $35,000. Caitong International Asset Management Co. Ltd raised its position in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company's stock valued at $59,000 after purchasing an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company's stock worth $63,000 after purchasing an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company's stock worth $63,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
